Two such mAbs, panitumumab and cetuximab, are active in metastatic colorectal cancer, but the clinical evidence shows that approximately 10% of patients achieve an objective tumor response to anti-EGFR mAbs [2]–[4]. This evidence concerns the gene EGFR and metastatic colorectal cancer.